Webcast to be Held at 8:00 am ET on Monday, August 14, 2023
WESTPORT, Conn., Aug. 7, 2023 /PRNewswire/ Intensity Therapeutics, Inc. , a clinical-stage biotechnology company focused on the.
Intensity Therapeutics Inc. (INTS) said that it has priced its upsized initial public offering of 3.90 million shares of common stock at a public offering price of $5.
WESTPORT, Conn., July 10, 2023 /PRNewswire/ Intensity Therapeutics, Inc. , a clinical-stage biotechnology company focused on the discovery and development of proprietary, novel immune-based.